JAK2 and hypertrophic cardiomyopathy: In confirmed hypertrophic cardiomyopathy (HCM) without JAK2-V617F mutation, upregulated expression of JAK2 in the global left ventricle (LV) and cardiomyocyte nuclei was observed, along with activation of its downstream target STAT3 (50).